Therapy context	Main neurologic pattern	Operational implication	Evidence level
Anti-CD19 CAR T-cell	Early encephalopathy, aphasia, seizure concern, EEG slowing	Structured monitoring and low threshold for clinically triggered EEG	Consensus, meta-analysis, trial, and observational evidence
CD3-engaging bispecific antibodies	Generally lower-grade events but repeated risk around step-up dosing	Observation, explicit escalation pathways, and continuity across settings	Meta-analysis, implementation guidance, and real-world cohorts
BCMA-directed CAR T-cell	Early ICANS plus delayed movement and neurocognitive syndromes	Extended symptom-specific follow-up after apparent recovery	Cohort safety signal plus case-report-level evidence for rare delayed phenotypes/rescue